Speaker(s): 

Lucas G. Hill, PharmD, FCCP, Staff Member, University of Pittsburgh School of Pharmacy - has reported the following disclosures: Kroger [Consultant/Advisor], Albertsons [Consultant/Advisor], Publix [Consultant/Advisor].

Moderator(s): 

Daniel Longyhore, PharmD, EdD, BCACP, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Identify key barriers and opportunities in pharmacy practice related to buprenorphine, naloxone, and syringe access.
• Analyze the impact of pharmacist engagement on retention rates in opioid use disorder treatment and the implications of recent and pending regulatory changes.
• Evaluate policy proposals, including methadone dispensing from community pharmacies, for their potential to enhance access to opioid use disorder treatment. 

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Daniel Longyhore, PharmD, EdD, BCACP; Eric Wright, PharmD, MPH; Melissa Kern, MPH and Lisabeth Karetsky, CPhT have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Sara Gaines, PharmD and Angela Slampak-Cindric, PharmD, BCPS

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None